Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
A Phase 1b, Randomized, Double-Blind, Active Comparator Controlled, 3-Period, Cross-Over Study To Characterize The Pharmacodynamics And Tolerability Of Two Dosing Regimens Of PF-04937319 In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated:  2/28/2014
Pfizer Investigational Site
mi
from
South Miami, FL
Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
A Phase 1b, Randomized, Double-Blind, Active Comparator Controlled, 3-Period, Cross-Over Study To Characterize The Pharmacodynamics And Tolerability Of Two Dosing Regimens Of PF-04937319 In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated: 2/28/2014
Pfizer Investigational Site
mi
from
South Miami, FL
Click here to add this to my saved trials
Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
A Phase 1b, Randomized, Double-Blind, Active Comparator Controlled, 3-Period, Cross-Over Study To Characterize The Pharmacodynamics And Tolerability Of Two Dosing Regimens Of PF-04937319 In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated:  2/28/2014
Pfizer Investigational Site
mi
from
High Point, NC
Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
A Phase 1b, Randomized, Double-Blind, Active Comparator Controlled, 3-Period, Cross-Over Study To Characterize The Pharmacodynamics And Tolerability Of Two Dosing Regimens Of PF-04937319 In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated: 2/28/2014
Pfizer Investigational Site
mi
from
High Point, NC
Click here to add this to my saved trials
Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
A Phase 1b, Randomized, Double-Blind, Active Comparator Controlled, 3-Period, Cross-Over Study To Characterize The Pharmacodynamics And Tolerability Of Two Dosing Regimens Of PF-04937319 In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated:  2/28/2014
Pfizer Investigational Site
mi
from
Cincinnati, OH
Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
A Phase 1b, Randomized, Double-Blind, Active Comparator Controlled, 3-Period, Cross-Over Study To Characterize The Pharmacodynamics And Tolerability Of Two Dosing Regimens Of PF-04937319 In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated: 2/28/2014
Pfizer Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
A Phase 1b, Randomized, Double-Blind, Active Comparator Controlled, 3-Period, Cross-Over Study To Characterize The Pharmacodynamics And Tolerability Of Two Dosing Regimens Of PF-04937319 In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated:  2/28/2014
Pfizer Investigational Site
mi
from
San Antonio, TX
Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
A Phase 1b, Randomized, Double-Blind, Active Comparator Controlled, 3-Period, Cross-Over Study To Characterize The Pharmacodynamics And Tolerability Of Two Dosing Regimens Of PF-04937319 In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated: 2/28/2014
Pfizer Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
A Phase 1b, Randomized, Double-Blind, Active Comparator Controlled, 3-Period, Cross-Over Study To Characterize The Pharmacodynamics And Tolerability Of Two Dosing Regimens Of PF-04937319 In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated:  2/28/2014
Pfizer Investigational Site
mi
from
West Bend, WI
Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
A Phase 1b, Randomized, Double-Blind, Active Comparator Controlled, 3-Period, Cross-Over Study To Characterize The Pharmacodynamics And Tolerability Of Two Dosing Regimens Of PF-04937319 In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated: 2/28/2014
Pfizer Investigational Site
mi
from
West Bend, WI
Click here to add this to my saved trials
mHealth Skill Enhancement Plus Phone CBT for Type 2 Diabetes Distress Medication Nonadherence: Pilot Study
mHealth Skill Enhancement Plus Phone CBT for Type 2 Diabetes Distress Medication Nonadherence: Pilot Study
Status: Enrolling
Updated:  3/6/2014
University of Pittsburgh School of Nursing
mi
from
Pittsburgh, PA
mHealth Skill Enhancement Plus Phone CBT for Type 2 Diabetes Distress Medication Nonadherence: Pilot Study
mHealth Skill Enhancement Plus Phone CBT for Type 2 Diabetes Distress Medication Nonadherence: Pilot Study
Status: Enrolling
Updated: 3/6/2014
University of Pittsburgh School of Nursing
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus
A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus
Status: Enrolling
Updated:  3/19/2014
Retinal Consultants of Arizona
mi
from
Phoenix, AZ
A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus
A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus
Status: Enrolling
Updated: 3/19/2014
Retinal Consultants of Arizona
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Adipose Derived Regenerative Cellular Therapy of Chronic Wounds
Adipose Derived Regenerative Cellular Therapy of Chronic Wounds
Status: Enrolling
Updated:  3/19/2014
Tower Outpatient Surgical Center
mi
from
Los Angeles, CA
Adipose Derived Regenerative Cellular Therapy of Chronic Wounds
Adipose Derived Regenerative Cellular Therapy of Chronic Wounds
Status: Enrolling
Updated: 3/19/2014
Tower Outpatient Surgical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics
A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics
Status: Enrolling
Updated:  3/20/2014
Orange County Research Center
mi
from
Tustin, CA
A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics
A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics
Status: Enrolling
Updated: 3/20/2014
Orange County Research Center
mi
from
Tustin, CA
Click here to add this to my saved trials
Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes
Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes
Status: Enrolling
Updated:  3/21/2014
University of Virginia, Center for Diabetes Technology
mi
from
Charlottesville, VA
Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes
Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes
Status: Enrolling
Updated: 3/21/2014
University of Virginia, Center for Diabetes Technology
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Status: Enrolling
Updated:  3/31/2014
AMCR Institute, Inc
mi
from
Escondido, CA
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Status: Enrolling
Updated: 3/31/2014
AMCR Institute, Inc
mi
from
Escondido, CA
Click here to add this to my saved trials
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Status: Enrolling
Updated:  3/31/2014
Diablo Clinical Research Inc
mi
from
Walnut creek, CA
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Status: Enrolling
Updated: 3/31/2014
Diablo Clinical Research Inc
mi
from
Walnut creek, CA
Click here to add this to my saved trials
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Status: Enrolling
Updated:  3/31/2014
Atlanta Diabetes Associates
mi
from
Atlanta, GA
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Status: Enrolling
Updated: 3/31/2014
Atlanta Diabetes Associates
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Status: Enrolling
Updated:  3/31/2014
Rainier Clinical Research Center Inc.
mi
from
Renton, WA
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Status: Enrolling
Updated: 3/31/2014
Rainier Clinical Research Center Inc.
mi
from
Renton, WA
Click here to add this to my saved trials
Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects
Phase 1, Randomized, Single-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of JTT-251 Single Oral Doses in Healthy Subjects (Part Ia) and in Type 2 Diabetic Subjects (Part Ib) and Randomized, Open-label, Crossover Study Evaluating Effect of Food on PK in Healthy Subjects (Part II)
Status: Enrolling
Updated:  4/4/2014
Clinical Research Facility
mi
from
Orlando, FL
Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects
Phase 1, Randomized, Single-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of JTT-251 Single Oral Doses in Healthy Subjects (Part Ia) and in Type 2 Diabetic Subjects (Part Ib) and Randomized, Open-label, Crossover Study Evaluating Effect of Food on PK in Healthy Subjects (Part II)
Status: Enrolling
Updated: 4/4/2014
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus
A 6-Week Phase 2a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 As Monotherapy In Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  4/8/2014
Pfizer Investigational Site
mi
from
Chula Vista, CA
A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus
A 6-Week Phase 2a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 As Monotherapy In Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 4/8/2014
Pfizer Investigational Site
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Investigating Markers of Energy Metabolism in the CNS and Periphery in Pregnant Women With Varying Degrees of Insulin Resistance
Status: Enrolling
Updated:  4/8/2014
Yale University
mi
from
New Haven, CT
Investigating Markers of Energy Metabolism in the CNS and Periphery in Pregnant Women With Varying Degrees of Insulin Resistance
Status: Enrolling
Updated: 4/8/2014
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Glendale, AZ
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Palm Springs, CA
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Denver, CO
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Boynton Beach, FL
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Debary, FL
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Debary, FL
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Hallandale Beach, FL
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Lakeland, FL
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Lakeland, FL
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Miami, FL
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Winter Haven, FL
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Winter Haven, FL
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Honolulu, HI
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Avon, IN
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Avon, IN
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
St. Louis, MO
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Hickory, NC
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Morehead City, NC
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Morehead City, NC
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Beavercreek, OH
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Beavercreek, OH
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Columbus, OH
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
East Providence, RI
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
East Providence, RI
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Charleston, SC
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Charleston, SC
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Kingsport, TN
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Kingsport, TN
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Ft. Worth, TX
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Ft. Worth, TX
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Houston, TX
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
San Antonio, TX
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Spring, TX
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Spring, TX
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  4/10/2014
Clinical Research Facility
mi
from
Salem, VA
Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 4/10/2014
Clinical Research Facility
mi
from
Salem, VA
Click here to add this to my saved trials
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
An Open-label, Single and Repeat Single Ascending Dose Escalation Study to Compare the Pharmacokinetics of Metformin Eicosapentaenoate With Metformin Hydrochloride and Icosapent Ethyl Following Oral Administration to Healthy Volunteers
Status: Enrolling
Updated:  4/10/2014
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
An Open-label, Single and Repeat Single Ascending Dose Escalation Study to Compare the Pharmacokinetics of Metformin Eicosapentaenoate With Metformin Hydrochloride and Icosapent Ethyl Following Oral Administration to Healthy Volunteers
Status: Enrolling
Updated: 4/10/2014
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of MK-3102 in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
A Multicenter, Phase III, Randomized, Placebo-controlled Trial to Assess the Safety and Efficacy of MK-3102 Monotherapy in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control
Status: Enrolling
Updated:  4/21/2014
Clinical Research Facility
mi
from
Oklahoma City, OK
A Study to Assess the Safety and Efficacy of MK-3102 in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
A Multicenter, Phase III, Randomized, Placebo-controlled Trial to Assess the Safety and Efficacy of MK-3102 Monotherapy in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control
Status: Enrolling
Updated: 4/21/2014
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Accuracy of Blood Glucose Detection by Diabetes Alert Dogs
Accuracy of Blood Glucose Detection by Diabetes Alert Dogs
Status: Enrolling
Updated:  4/28/2014
University of Virginia Center for Behavioral Medicine Research
mi
from
Charlottesville, VA
Accuracy of Blood Glucose Detection by Diabetes Alert Dogs
Accuracy of Blood Glucose Detection by Diabetes Alert Dogs
Status: Enrolling
Updated: 4/28/2014
University of Virginia Center for Behavioral Medicine Research
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™ - Intensification)
Status: Enrolling
Updated:  5/8/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Fresno, CA
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™ - Intensification)
Status: Enrolling
Updated: 5/8/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Fresno, CA
Click here to add this to my saved trials
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™ - Intensification)
Status: Enrolling
Updated:  5/8/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Lexington, KY
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™ - Intensification)
Status: Enrolling
Updated: 5/8/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Lexington, KY
Click here to add this to my saved trials
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™ - Intensification)
Status: Enrolling
Updated:  5/8/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Slidell, LA
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™ - Intensification)
Status: Enrolling
Updated: 5/8/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Slidell, LA
Click here to add this to my saved trials
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™ - Intensification)
Status: Enrolling
Updated:  5/8/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Tipton, PA
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™ - Intensification)
Status: Enrolling
Updated: 5/8/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Tipton, PA
Click here to add this to my saved trials
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™ - Intensification)
Status: Enrolling
Updated:  5/8/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Renton, WA
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™ - Intensification)
Status: Enrolling
Updated: 5/8/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Renton, WA
Click here to add this to my saved trials